ConductScience.org, home
Papers
API referenceFor AI assistants

Paper · 24423918

S0941: a phase 2 SWOG study of sorafenib and erlotinib in patients with advanced gallbladder carcinoma or cholangiocarcinoma.

El-Khoueiry AB and 8 others. Br J Cancer, 2014. Cited by 94 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. S0941: a phase 2 SWOG study of sorafenib and erlotinib in patients with advanced gallbladder carcinoma or cholangiocarcinoma. Papers, record 24423918. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/24423918

On this page

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
S0941: a phase 2 SWOG study of sorafenib and erlotinib in patients with advanced gallbladder carcinoma or cholangiocarcinoma.
PubMed
Journal
Br J Cancer
PubMed
Year
2014
PubMed
Publication types
Clinical Trial, Phase II, Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
94
iCite
Relative citation ratio, by iCite
2.8
iCite
Revised in PubMed
2022-03-30
PubMed

Authors9

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1El-Khoueiry ABA B
2Rankin CC
3Siegel ABA B
4Iqbal SS
5Gong IYI-Y
6Micetich KCK C
7Kayaleh ORO R
8Lenz HJH-J
9Blanke CDC D

Source PubMed

Topics22

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antineoplastic Combined Chemotherapy ProtocolsMajor topic
Bile Duct NeoplasmsMajor topic
Bile Ducts, IntrahepaticMajor topic
CholangiocarcinomaMajor topic
Gallbladder NeoplasmsMajor topic
NiacinamideMajor topic
Phenylurea CompoundsMajor topic
Protein Kinase InhibitorsMajor topic
QuinazolinesMajor topic
Aged
Aged, 80 and over
Disease-Free Survival
ErbB Receptors
Erlotinib Hydrochloride
Female
Humans
MAP Kinase Signaling System
Male
Middle Aged
Sorafenib
Treatment Failure
Vascular Endothelial Growth Factor A

Source PubMed

Grants35

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated bySource
N01 CA035431NCI NIH HHSUnited StatesU10CA035431PubMed and NIHNIH RePORTER
CA20319NCI NIH HHSUnited StatesR10CA020319PubMed and NIHNIH RePORTER
N01 CA032102NCI NIH HHSUnited StatesU10CA032102PubMed and NIHNIH RePORTER
N01 CA013612NCI NIH HHSUnited StatesR10CA013612PubMed and NIHNIH RePORTER
U10 CA013612NCI NIH HHSUnited StatesR10CA013612PubMed and NIHNIH RePORTER
N01 CA045807NCI NIH HHSUnited StatesU10CA045807PubMed and NIHNIH RePORTER
CA58882NCI NIH HHSUnited StatesU10CA058882PubMed and NIHNIH RePORTER
K23 CA149084NCI NIH HHSUnited StatesK23CA149084PubMed and NIHNIH RePORTER
CA16385NCI NIH HHSUnited StatesR10CA016385PubMed and NIHNIH RePORTER
U10 CA032102NCI NIH HHSUnited StatesU10CA032102PubMed and NIHNIH RePORTER

1 to 10 of 35

See all 35 grants

Trials0

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

None in this release.

Comments and corrections0

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

None in this release.

References25

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
116,505,435Differential cell cycle-regulatory protein expression in biliary tract adenocarcinoma: correlation with anatomic site, pathologic variables, and clinical outcome.J Clin Oncol2006https://conductscience.org/library/papers/16505435PubMed
220,197,396Phase I combination of sorafenib and erlotinib therapy in solid tumors: safety, pharmacokinetic, and pharmacodynamic evaluation from an expansion cohort.Mol Cancer Ther2010https://conductscience.org/library/papers/20197396PubMed
324,139,215The frequency of KRAS and BRAF mutations in intrahepatic cholangiocarcinomas and their correlation with clinical outcome.Hum Pathol2013https://conductscience.org/library/papers/24139215PubMed
421,748,296SWOG 0514: a phase II study of sorafenib in patients with unresectable or metastatic gallbladder carcinoma and cholangiocarcinoma.Invest New Drugs2012https://conductscience.org/library/papers/21748296PubMed
512,692,057Mutations of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinoma.Gut2003https://conductscience.org/library/papers/12692057PubMed
611,980,649ZD1839 (Iressa) induces antiangiogenic effects through inhibition of epidermal growth factor receptor tyrosine kinase.Cancer Res2002https://conductscience.org/library/papers/11980649PubMed
714,760,102Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy.Clin Cancer Res2004https://conductscience.org/library/papers/14760102PubMed
823,182,627Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study.Lancet Oncol2013https://conductscience.org/library/papers/23182627PubMed
923,391,413Molecular profiling of cholangiocarcinoma shows potential for targeted therapy treatment decisions.Hum Pathol2013https://conductscience.org/library/papers/23391413PubMed
107,680,247Epidermal growth factor stimulates vascular endothelial growth factor production by human malignant glioma cells: a model of glioblastoma multiforme pathophysiology.Mol Biol Cell1993https://conductscience.org/library/papers/7680247PubMed

1 to 10 of 25

See all 25 references

Cited by58

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 94 citations.

PMIDTitleJournalYearIn PapersSource
41,226,789Expanding Horizons in Cholangiocarcinoma: Emerging Targets Beyond FGFR2 and IDH1.Int J Mol Sci2025https://conductscience.org/library/papers/41226789PubMed
40,693,603Targeted therapies and immunotherapies for unresectable cholangiocarcinoma.Chin Med J (Engl)2025https://conductscience.org/library/papers/40693603PubMed
40,208,392Intrahepatic cholangiocarcinoma patient with epidermal growth factor receptor exon 19 deletion unresponsive to Afatinib monotherapy: a case report.Discov Oncol2025https://conductscience.org/library/papers/40208392PubMed
39,881,555Integration of circulating tumor DNA in biliary tract cancer: the emerging landscape.Hepat Oncol2024https://conductscience.org/library/papers/39881555PubMed
38,751,699Therapeutic Outcome of Multidisciplinary Treatment in Unresectable Biliary Tract Cancer: A Multicenter Retrospective Analysis.World J Oncol2024https://conductscience.org/library/papers/38751699PubMed
38,730,642Current and Future Therapeutic Targets for Directed Molecular Therapies in Cholangiocarcinoma.Cancers (Basel)2024https://conductscience.org/library/papers/38730642PubMed
36,854,604
Afatinib in combination with GEMOX chemotherapy as the adjuvant treatment in patients with ErbB pathway mutated, resectable gallbladder cancer: study protocol for a ctDNA-based, multicentre, open-label, randomised, controlled, phase II trial.
BMJ Open2023https://conductscience.org/library/papers/36854604PubMed
36,643,047Combination Therapies for Advanced Biliary Tract Cancer.J Clin Transl Hepatol2023https://conductscience.org/library/papers/36643047PubMed
36,612,035Efficacy and Safety of First-Line Targeted Treatment and Immunotherapy for Patients with Biliary Tract Cancer: A Systematic Review and Meta-Analysis.Cancers (Basel)2022https://conductscience.org/library/papers/36612035PubMed
36,559,193Suppressing of Src-Hic-5-JNK-AKT Signaling Reduced GAPDH Expression for Preventing the Progression of HuCCT1 Cholangiocarcinoma.Pharmaceutics2022https://conductscience.org/library/papers/36559193PubMed

1 to 10 of 58

See all 58 cited by

Genes13

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
BRAF673PubTator's text mininghttps://conductscience.org/library/genes/673NCBI Gene
CXCL83,576PubTator's text mininghttps://conductscience.org/library/genes/3576NCBI Gene
EGFR1,956PubTator's text mininghttps://conductscience.org/library/genes/1956NCBI Gene
ERBB22,064PubTator's text mininghttps://conductscience.org/library/genes/2064NCBI Gene
KDR3,791PubTator's text mininghttps://conductscience.org/library/genes/3791NCBI Gene
KRAS3,845PubTator's text mininghttps://conductscience.org/library/genes/3845NCBI Gene
MAP2K75,609PubTator's text mininghttps://conductscience.org/library/genes/5609NCBI Gene
MAPK15,594PubTator's text mininghttps://conductscience.org/library/genes/5594NCBI Gene
SLC17A526,503PubTator's text mininghttps://conductscience.org/library/genes/26503NCBI Gene
SLTM79,811PubTator's text mininghttps://conductscience.org/library/genes/79811NCBI Gene

1 to 10 of 13

See all 13 genes

Drugs0

The drugs whose trials, in the Pipelines release, list the paper.

None in this release.

Data0

The data bank entries PubMed's record names. Trial numbers are under Trials.

None in this release.

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/24423918

GET https://conductscience.org/api/papers/v1/24423918/grants?page=2

API referenceFor AI assistants